Factors connected with efficacy of single ketamine infusion in bipolar depression

Psychiatria Polska

Volumn 48, Issue 1, 2014, Pages 35-47

  Permoda Osip, Agnieszka ^a   Skibińska, Maria ^a   Śniatkowska, Alicja Bartkowska ^a   Kliwicki, Sebastian ^a   Chłopocka Woźniak, Maria ^a   Rybakowski, Janusz K ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Antidepressant drugs; Bipolar depression; Ketamine

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; CITALOPRAM; CLOMIPRAMINE; CYANOCOBALAMIN; DULOXETINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FOLIC ACID; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; KETAMINE; LITHIUM CARBONATE; MIANSERIN; MIRTAZAPINE; NEURITE PROMOTING FACTOR; NEUROTROPHIN; NEUROTROPHIN 3; NEUROTROPHIN 4; PAROXETINE; QUETIAPINE; REBOXETINE; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VENLAFAXINE; ANTIDEPRESSANT AGENT;

ADULT; AGED; ALCOHOLISM; ANTIDEPRESSANT ACTIVITY; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FAMILY HISTORY; FEMALE; HAMILTON SCALE; HUMAN; INFLAMMATION; MALE; MIDDLE AGED; PROTEIN BLOOD LEVEL; REMISSION; SINGLE DRUG DOSE; VITAMIN BLOOD LEVEL; YOUNG ADULT; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; PSYCHOLOGICAL RATING SCALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84894254989     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: 10.12740/pp/21175     Document Type: Article

References (31)

1. Rybakowski J. Depresja lekooporna: rozpoznawanie i postepowanie. Przewodnik Lekarza 2012; 15: 104-109.
2. Permoda-Osip A, Rybakowski J. Rola układu glutaminergicznego w mechanizmie działania przeciwdepresyjnego i normotymicznego w chorobach afektywnych. Farmakoterapia w Psychiatrii i Neurologii 2011; 27: 57-65.
3. Boyer PA, Skolnick P, Fossom LH. Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study. J Mol Neurosci. 1998; 10: 219-33.
4. Martinez-Turrillas R, Frechilla D, Del Rio J: Chronic antidepressant treatment increases the membrane expression of AMPA receptors in rat hippocampus. Neuropharmacology 2002; 43: 1230-1237.
5. Martinez-Turrillas R, Del Rio J, Frechilla D: Sequential changes in BDNF mRNA expression and synaptic levels of AMPA receptor subunits in rat hippocampus after chronic antidepressant treatment. Neuropharmacology 2005; 49: 1178-1188.
6. Bobula B, Hess G: Antidepressant treatments-induced modifications of glutamatergic transmission in rat frontal cortex. Pharmacol Rep 2008; 60: 865-871.
7. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS i wsp. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-354.
8. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA i wsp. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-864.
9. Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009; 66: 522-526.
10. Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011; 14: 1127-1131.
11. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S i wsp. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010; 67: 793-802.
12. Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A i wsp. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012; 71: 939-946.
13. Salvadore G, Singh JB. Ketamine as a fast acting antidepressant: current knowledge and open questions. CNS Neurosci Ther 2013; 19: 428-436.
14. Rasmussen KG, Lineberry TW, Galardy CW, Kung S, Lapid MI, Palmer BA i wsp. Serial infusions of low-dose ketamine for major depression. J psychopharmacol 2013; 27: 444-450.
15. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM i wsp. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013; 170: 1134-1142.
16. Katalinic N, Lai R, Somogyi A, Mitchell PB, Glue P, Loo CK. Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Aust N Z J Psychiatry 2013; 47: 710-727.
17. Permoda-Osip A, Adamski R, Bartkowska-Śniatkowska A, Chłopocka-Woźniak M, Rybakowski JK. Skuteczność jednorazowego wlewu ketaminy w depresji w przebiegu choroby afektywnej dwubiegunowej przy braku poprawy po lekach przeciwdepresyjnych. Framakoterapia w Psychiatrii i Neurologii 2012; 28: 81-86.
18. Rybakowski JK. Two generations of mood stabilizers. Int J Neuropsychopharmacol 2007; 10: 709-711.
19. Covvey JR, Crawford AN, Lowe DK: Intravenous ketamine for treatment-resistant major depressive disorder. Ann Pharmacother 2012; 46: 117-123.
20. Luckenbaugh DA, Ibrahim L, Brutsche N, Franco-Chaves J, Mathews D, Marquardt CA i wsp. Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. Bipolar Disord 2012; 14: 880-887.
21. Chandrasekar R. Alcohol and NMDA receptor: current research and future direction. Front Mol Neurosci 2013; 6: 14.
22. Hintikka J, Tolmunen T, Tanskanen A, Viinamäki H. High vitamin B12 level and good treatment outcome may be associated in major depressive disorder. BMC Psychiatry 2003; 3: 17.
23. Kate N, Grover S, Agarwal M. Does B12 deficiency lead to lack of treatment response to conventional antidepressants? Psychiatry 2010; 7: 42-44.
24. Permoda-Osip A, Dorszewska J, Bartkowska-Sniatkowska A, Chłopocka-Wozniak M, Rybakowski JK. Vitamin B12 level may be related to the efficacy of single ketamine infusion in bipolar depression. Pharmacopsychiatry 2013; 46: 227-228.
25. Gu P, DeFina LF, Leonard D, John S, Weiner MF, Brown ES. Relationship between serum homocysteine levels and depressive symptoms: The Cooper Center Longitudinal Study. J Clin Psychiatry 2012; 73: 691-695.
26. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF i wsp. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011; 475: 91-95.
27. Machado-Vieira R, Yuan P, Brutsche N, DiazGranados N, Luckenbaugh D, Manji HK i wsp. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry 2009; 70: 1662-1666.
28. Rybakowski JK, Permoda-Osip A, Skibinska M, Adamski R, Bartkowska-Sniatkowska A. Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved? Hum Psychopharmacol 2013; 28: 87-90.
29. Haile CN, Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Foulkes A i wsp. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuroppsychopharmacol 2013; Oct 8 [e-pub ahead of print].
30. Nowacka MM, Obuchowicz E. Vascular endothelial growth factor (VEGF) and its role in the central nervous system: a new element in the neurotrophic hypothesis of antidepressant drug action. Neuropeptides 2012; 46: 1-10.
31. Gałecki P, Orzechowska A, Berent D, Talarowska M, Bobińska K, Gałecka E i wsp. Vascular endothelial growth factor receptor 2 gene (KDR) polymorphisms and expression levels in depressive disorder. J. Affect. Disord. 2013; 147: 144-149.